Sernova Corp is working to develop a functional cure for type 1 diabetes that could free patients from a lifetime of insulin injections, but despite some early encouraging clinical data and a potentially large commercial opportunity, the company is running low on cash and is competing against a well-capitalized rival.
Key Takeaways
- Sernova is looking to complete a round of financing and would consider a potential partnership with a larger pharmaceutical player, CEO Cynthia Pussinen said.
The small Canadian biotech needs to complete a round of financing and would consider a potential partnership with a larger...